Cargando…

Stimulation of noradrenergic transmission by reboxetine is beneficial for a mouse model of progressive parkinsonism

Parkinson’s disease (PD) is the second most common neurodegenerative disorder and is characterized by motor deficits such as tremor, rigidity and bradykinesia. These symptoms are directly caused by the loss of dopaminergic neurons. However, a wealth of clinical evidence indicates that the dopaminerg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kreiner, Grzegorz, Rafa-Zabłocka, Katarzyna, Barut, Justyna, Chmielarz, Piotr, Kot, Marta, Bagińska, Monika, Parlato, Rosanna, Daniel, Władysława Anna, Nalepa, Irena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437187/ https://www.ncbi.nlm.nih.gov/pubmed/30918302 http://dx.doi.org/10.1038/s41598-019-41756-3

Ejemplares similares

Transgenic mice lacking CREB and CREM in noradrenergic and serotonergic neurons respond differently to common antidepressants on tail suspension test
por: Rafa–Zabłocka, Katarzyna, et al.
Publicado: (2017)

Lack of riluzole efficacy in the progression of the neurodegenerative phenotype in a new conditional mouse model of striatal degeneration
por: Kreiner, Grzegorz, et al.
Publicado: (2017)

Inactivation of Glucocorticoid Receptor in Noradrenergic System Influences Anxiety- and Depressive-Like Behavior in Mice
por: Chmielarz, Piotr, et al.
Publicado: (2013)

Selective Depletion of CREB in Serotonergic Neurons Affects the Upregulation of Brain-Derived Neurotrophic Factor Evoked by Chronic Fluoxetine Treatment
por: Rafa-Zabłocka, Katarzyna, et al.
Publicado: (2018)

Chronic restraint stress induces changes in the cerebral Galpha 12/13 and Rho-GTPase signaling network
por: Rafa-Zabłocka, Katarzyna, et al.
Publicado: (2021)

Antidepressants Differentially Regulate Intracellular Signaling from α1-Adrenergic Receptor Subtypes In Vitro
por: Chmielarz, Piotr, et al.
Publicado: (2021)

Investigating the potential effects of α-synuclein aggregation on susceptibility to chronic stress in a mouse Parkinson’s disease model
por: Alwani, Anna, et al.
Publicado: (2023)

Local and Global Resting State Activity in the Noradrenergic and Dopaminergic Pathway Modulated by Reboxetine and Amisulpride in Healthy Subjects
por: Metzger, Coraline D, et al.
Publicado: (2015)

Nucleolar activity in neurodegenerative diseases: a missing piece of the puzzle?
por: Parlato, Rosanna, et al.
Publicado: (2012)

Reboxetine-induced urinary hesitancy
por: Borade, Suresh, et al.
Publicado: (2005)

Integration of the Deacetylase SIRT1 in the Response to Nucleolar Stress: Metabolic Implications for Neurodegenerative Diseases
por: Kreiner, Grzegorz, et al.
Publicado: (2019)

Cell Culture Media, Unlike the Presence of Insulin, Affect α-Synuclein Aggregation in Dopaminergic Neurons
por: Hlushchuk, Irena, et al.
Publicado: (2022)

The Noradrenergic System in Parkinson’s Disease
por: Paredes-Rodriguez, Elena, et al.
Publicado: (2020)

Effects of reboxetine and citalopram on appraisal of infant facial expressions and attentional biases
por: Stein, Alan, et al.
Publicado: (2012)

Pharmacological Blockade of Spinal CXCL3/CXCR2 Signaling by NVP CXCR2 20, a Selective CXCR2 Antagonist, Reduces Neuropathic Pain Following Peripheral Nerve Injury
por: Piotrowska, Anna, et al.
Publicado: (2019)

Involvement of Macrophage Inflammatory Protein-1 Family Members in the Development of Diabetic Neuropathy and Their Contribution to Effectiveness of Morphine
por: Rojewska, Ewelina, et al.
Publicado: (2018)

Dopaminergic, serotonergic, and noradrenergic deficits in Parkinson disease
por: Buddhala, Chandana, et al.
Publicado: (2015)

Gut Microbiome Alteration after Reboxetine Administration in Type-1 Diabetic Rats
por: Aydin, Sinem, et al.
Publicado: (2021)

Anti-Candidal Activity of Reboxetine and Sertraline Antidepressants: Effects on Pre-Formed Biofilms
por: Ahmed, Eman Ibrahim, et al.
Publicado: (2023)

Targeted Depletion of Primary Cilia in Dopaminoceptive Neurons in a Preclinical Mouse Model of Huntington’s Disease
por: Mustafa, Rasem, et al.
Publicado: (2019)

New insights into the analgesic properties of the XCL1/XCR1 and XCL1/ITGA9 axes modulation under neuropathic pain conditions - evidence from animal studies
por: Ciechanowska, Agata, et al.
Publicado: (2022)

Neuroprotective Effects of Pomegranate Juice against Parkinson’s Disease and Presence of Ellagitannins-Derived Metabolite—Urolithin A—In the Brain
por: Kujawska, Małgorzata, et al.
Publicado: (2019)

Dying-back of ascending noradrenergic projections in Parkinson’s disease
por: Helmich, Rick C, et al.
Publicado: (2021)

Restoration of Noradrenergic Function in Parkinson’s Disease Model Mice
por: Cui, Kui, et al.
Publicado: (2021)

Impact of reboxetine plus oxybutynin treatment for obstructive sleep apnea on cardiovascular autonomic modulation
por: Perger, Elisa, et al.
Publicado: (2023)

O001 Reboxetine reduces obstructive sleep apnea severity: a randomized trial
por: Altree, T, et al.
Publicado: (2021)

The selective norepinephrine reuptake inhibitor reboxetine promotes late-stage fracture healing in mice
por: Donat, Antonia, et al.
Publicado: (2023)

DPCPX, a selective adenosine A1 receptor antagonist, enhances the antidepressant-like effects of imipramine, escitalopram, and reboxetine in mice behavioral tests
por: Szopa, Aleksandra, et al.
Publicado: (2018)

Reboxetine Improves Auditory Attention and Increases Norepinephrine Levels in the Auditory Cortex of Chronically Stressed Rats
por: Pérez-Valenzuela, Catherine, et al.
Publicado: (2016)

Noradrenergic Dysfunction in Alzheimer's and Parkinson's Diseases—An Overview of Imaging Studies
por: Peterson, Andrew C., et al.
Publicado: (2018)

A comparison of the effects of reboxetine and placebo on reaction time in adults with Attention Deficit-Hyperactivity Disorder (ADHD)
por: Hashemian, F, et al.
Publicado: (2011)

Exploring the Inhibitory Mechanism of Approved Selective Norepinephrine Reuptake Inhibitors and Reboxetine Enantiomers by Molecular Dynamics Study
por: Zheng, Guoxun, et al.
Publicado: (2016)

Effectiveness of Reboxetine in Treatment of Outpatient Children and Adolescents with Attention Deficit-Hyperactivity Disorder with Comorbid Anxiety Disorders
por: Riahi, Forough, et al.
Publicado: (2013)

α-Synuclein and Noradrenergic Modulation of Immune Cells in Parkinson’s Disease Pathogenesis
por: Butkovich, Laura M., et al.
Publicado: (2018)

Alpha adrenergic modulation on effects of norepinephrine transporter inhibitor reboxetine in five-choice serial reaction time task
por: Liu, Yia-Ping, et al.
Publicado: (2009)

Erotic Stimulus Processing under Amisulpride and Reboxetine: A Placebo-Controlled fMRI Study in Healthy Subjects
por: Graf, Heiko, et al.
Publicado: (2015)

Targeting the noradrenergic system for anti-inflammatory and neuroprotective effects: implications for Parkinson's disease
por: O’Neill, Eoin, et al.
Publicado: (2018)

Noradrenergic deficits contribute to apathy in Parkinson’s disease through the precision of expected outcomes
por: Hezemans, Frank H., et al.
Publicado: (2022)

Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials
por: Eyding, Dirk, et al.
Publicado: (2010)

Targeted Ablation of Primary Cilia in Differentiated Dopaminergic Neurons Reduces Striatal Dopamine and Responsiveness to Metabolic Stress
por: Mustafa, Rasem, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_q808j4962si32enj7m7s1p98lp